The anti-biofilm wound dressing market size is expected to advance at a CAGR of 8.9% during 2022–2030, to reach USD 1,447 million by 2030, ascribed to the growing number of ambulatory surgery centers.
Moreover, the increasing prevalence of diabetes and growing number of cases of chronic injuries are expected to propel the growth. The management of traumatic injuries majorly involves repairing the damage to the underlying tissue in the skin and draining the wounds. Moreover, the rise in the count of burn cases is forecast to boost the demand for these products over the coming years.
The risk of developing a diabetic foot ulcer in the lifetime is between 19% and 34%. In addition, 9.1 to 26.1 million diabetic foot ulcers are diagnosed annually across the world. In this regard, the growing aging population is propelling the growth of the market.
The number of surgeries is increasing in full-fledged hospitals and ambulatory centers across the world, which, in turn, boosts the demand for anti-biofilm wound dressings. The main purpose of dressing the incision is to absorb leakage from the injury and protect the area until it is healed. Heart surgeries are common because of the unhealthy dietary habits and lifestyles. More than 500,000 open heart surgery are performed every year in the U.S. Similarly, in 2021, approximately 7 million orthopedic surgeries were performed in U.S., according to government websites.
Due to the high count of surgeries performed every year, the requirement for dressings is rising to prevent infection and minimize scarring at the time of the healing of surgical lesions.
The APAC region is expected to grow with a CAGR of about 10.2% over this decade. The increasing number of obese and diabetic patients, coupled with the rising aging population, propels the use of anti-biofilm wound dressing products. According to government sites, one in four people is above 65 years of age in APAC. The aging population is at a high risk of various diseases and disabilities, which would propel the demand for wound care products. Moreover, the medical tourism industry is growing in this region, in turn, propelling the market.
Europe holds the second-leading position in the anti-biofilm wound dressing market.In addition, the Conference of the European Wound Management Association (EWMA) was held in Paris in 2022. Such awareness initiatives by various organizations, growing count of government initiatives, and increasing number of people with chronic injuries are expected to propel the demand for these products in the region.
The LATAM market is also expected to grow at a considerable rate in the coming years. The availability of advanced treatment options at a low cost makes the region a preferred destination for medical tourism.
The most-significant anti-biofilm wound dressing market players are Convatec Inc., 3M Company, B. Braun SE, Urgo Ltd., Coloplast Group, Imbed Biosciences Inc., Lohmann & Rauscher GmbH & Co. KG, Next Science Ltd., and Smith & Nephew plc.